A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4(+) T-cell response

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

  • Kasper Karlsen
  • Karen Smith Korsholm
  • Rasmus Mortensen
  • Seyed Mojtaba Ghiasi
  • Peter Andersen
  • Foged, Camilla
  • Dennis Christensen

AIM: To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity.

MATERIALS & METHODS: Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.

RESULTS: DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.

CONCLUSION: The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.

OriginalsprogEngelsk
TidsskriftNanomedicine
Vol/bind9
Udgave nummer17
Sider (fra-til)2625-38
Antal sider14
ISSN1743-5889
DOI
StatusUdgivet - dec. 2014

ID: 129781428